Sign on to support the OPEN ACT - Orphan Product Extensions Now, Accelerating Cures & Treatments. The OPEN ACT could bring hundreds of safe, effective, and affordable medicines to rare disease patients within the next several years by incentivizing drug makers to repurpose therapies for the treatment of life-threatening rare diseases and pediatric cancers. EveryLife Foundation, the National Organization for Rare Disorders (NORD), Global Genes, Genetic Alliance and an additional 169 patient organizations support this bipartisan legislation.
Click here to learn more about the OPEN ACT and how it can benefit rare disease patients.
Please take a minute to sign your organization on in support and share this page on social media!
Check the box below to indicate your support for the OPEN ACT: